Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Apr 30, 2024 7:05pm
116 Views
Post# 36016146

RE:RE:RE:RE:RE:“Conference call to discuss “A” corporate update”….

RE:RE:RE:RE:RE:“Conference call to discuss “A” corporate update”….

I can only go by past history. ( I have been in the stock market since 1978). Long before Buck was born.
past history & protocols.
Word smithing is a dangerous game. 

in any incidence you need to look at context, situations & protocols.
To suggest my interpretation is rain8ng on a parade? Bucky can only see negative. He has the mind of a 12 year old.
regardless of the announcement of Q1 update or updates.
We still have pending results from the FDA request for  MBc phase 3.
on- going increased enrolment with the Goblet/ Roshe studies.
pending news with Pancreatic cancer phase 3.
two recently announced abstracts at the upcoming ASCO conference 
These are ALL great progress items, needing an update.
A partership and/ or. Buyout could happen tomorrow?
That business development must happen & soon.
To tomorrow, next week, next month....
The items to be dealt with happen exclusively of each other.
Back to my most recent buyout experience.
They had year end results. Talked about recent new hires. Moving some duties in-house instead of contracting....all business as normal.
The Q1 update notice went out exact same as always.
about a week before that happened, the take over N.R. Came out.
Point.
Assuming there is negotiations going on, everything has to stay status quo until the deal can be made public.
reason?
in sales, it's not over until it's over..
I was in sales for 3 years. One of my colegues had a potential very large order on his report for many quarters.
He was dealing direct with the owner. He gave that order a 99% probability of closing.
Then one day, driving into work he hears on the radio, the company he was selling to was just bought out by a USA conglomerate.
His 95% went to zero%.
negotiations can be long drawn out & effected by many things out of even the principles of the deal control.
So, things carry on as-is, until the ink is dried.
Does not mean the Q1 update won't include a buyout or partnership announcement.
That however would be a N..R. First.
At this stage anything is possible.
saying it won't happen because it hasn't yet, is silly.
the SP is down because PanCan cancelled leaving a big gap.
Reminder, PanCan did still maintain its $5 miillion grant so Onc could expand its pancreatic cancer options.
A huge indicator of confidence.

 

<< Previous
Bullboard Posts
Next >>